Aliskiren Monotherapy Does Not Cause Paradoxical Blood Pressure Rises
- 1 January 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hypertension
- Vol. 55 (1), 54-60
- https://doi.org/10.1161/hypertensionaha.109.135772
Abstract
Angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, and diuretics all cause reactive rises in plasma renin concentration, but particularly high levels have been reported with aliskiren. This prompted speculation that blockade of plasma renin activity with aliskiren could be overwhelmed, leading to paradoxical increases in blood pressure. This meta-analysis of data from 4877 patients from 8 randomized, double-blind, placebo- and/or active-controlled trials examined this hypothesis. The analysis focused on the incidence of paradoxical blood pressure increases above predefined thresholds, after ≥4 weeks of treatment with 300 mg of aliskiren, angiotensin receptor blockers (300 mg of irbesartan, 100 mg of losartan, or 320 mg of valsartan), 10 mg of ramipril, 25 mg of hydrochlorothiazide, or placebo. There were no significant differences in the frequency of increases in systolic (>10 mm Hg; P =0.30) or diastolic (>5 mm Hg; P =0.65) pressure among those treated with aliskiren (3.9% and 3.1%, respectively), angiotensin receptor blockers (4.0% and 3.7%), ramipril (5.7% and 2.6%), or hydrochlorothiazide (4.4% and 2.7%). Increases in blood pressure were considerably more frequent in the placebo group (12.6% and 11.4%; P 10 mm Hg that was associated with an increase in plasma renin activity >0.1 ng/mL per hour. In conclusion, the incidence of blood pressure increases with aliskiren was similar to that during treatment with other antihypertensive drugs. Blood pressure rises on aliskiren treatment were not associated with increases in plasma renin activity. This meta-analysis found no evidence that aliskiren uniquely causes paradoxical rises in blood pressure.Keywords
This publication has 20 references indexed in Scilit:
- Aliskiren Fails to Lower Blood Pressure in Patients Who Have Either Low PRA Levels or Whose PRA Falls Insufficiently or Reactively RisesAmerican Journal of Hypertension, 2009
- It Is the Plasma Renin Activity Level That Counts, not StoichiometryHypertension, 2008
- Aliskiren-Binding Increases the Half Life of Renin and Prorenin in Rat Aortic Vascular Smooth Muscle CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Renin Inhibition by Aliskiren Prevents Atherosclerosis ProgressionHypertension, 2008
- The Renin Rise With Aliskiren: It’s Simply StoichiometryHypertension, 2008
- Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertensionInternational Journal of Clinical Practice, 2007
- Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its EffectivenessAmerican Journal of Hypertension, 2007
- AliskirenDrugs, 2007
- Renin inhibition with aliskiren: where are we now, and where are we going?Journal of Hypertension, 2006
- Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100)Hypertension, 2002